TACE
These models predict survival after Trans ArterialChemoEmbolisation (TACE) as primary palliative treatment for Hepatocellular Carcinoma. The first model is applicable before TACE treatment; the second is a refined estimate applicable when the response category (obtained 6-9 weeks after the initial TACE) has been defined.